IDV vehicle
75N95024D00002
CLINICAL EVALUATION OF PHENSERINE TARTRATE EXTENDED CONTROLLED RELEASE TABLET (ECRT) FORMULATION IN EARLY MILD ALZHEIMER'S DISEASE AND MILD TO MODERATE TRAUMATIC BRAIN INJURY.
Award details
Obligations, current value and potential value describe different measures; they are never added together.
| Field | Reported value |
|---|---|
| Agency | Department of Health and Human Services |
| Office | NATIONAL INSTITUTES OF HEALTH NIDA |
| NAICS | 541990 — All Other Professional, Scientific, and Technical Services |
| PSC | B504 — Chemical/Biological Studies and Analysis |
| Parent award / vehicle | Not reported |
| Set-aside | NO SET ASIDE USED. |
| Pricing type | COST NO FEE |
| Obligations | $0 |
| Current contract value | Not reported |
| Potential contract value / ceiling | $2.0M |
| Start date | Feb 1, 2024 |
| Current end date | Not available |
| Potential end date | Not available |
| Latest award activity | Aug 3, 2026 |
| Source loaded | Sep 26, 2026 |
Funding and modification history
Showing the latest 3 of 3 loaded transactions. Negative values are deobligations.
| Date | Modification | Obligation change | Description |
|---|---|---|---|
| Aug 3, 2026 | P00002 | $0 | CLINICAL EVALUATION OF PHENSERINE TARTRATE EXTENDED CONTROLLED RELEASE TABLET (ECRT) FORMULATION IN EARLY MILD ALZHEIMER'S DISEASE AND MILD TO MODERATE TRAUMATIC BRAIN INJURY. |
| Jan 21, 2025 | P00001 | $0 | CLINICAL EVALUATION OF PHENSERINE TARTRATE EXTENDED CONTROLLED RELEASE TABLET (ECRT) FORMULATION IN EARLY MILD ALZHEIMER'S DISEASE AND MILD TO MODERATE TRAUMATIC BRAIN INJURY. |
| Jan 29, 2024 | 0 | $0 | CLINICAL EVALUATION OF PHENSERINE TARTRATE EXTENDED CONTROLLED RELEASE TABLET (ECRT) FORMULATION IN EARLY MILD ALZHEIMER'S DISEASE AND MILD TO MODERATE TRAUMATIC BRAIN INJURY. |
Buyer contacts from matching notices
Matched on exact award/solicitation identifier and awarding agency. Source dates describe the notice, not current contact verification.
Research next steps
- Check the stated set-aside against the solicitation and current certifications.
- Review the award scope and buyer evidence before making a bid/no-bid decision.